ClinicalTrials.gg
RecruitingNCT07046559Updated Mar 3, 2026

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants

A Phase 1 interventional study of LY4066708 and Placebo in Healthy and Cancer, sponsored by Eli Lilly and Company. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant.

02

Conditions studied

  • Healthy
  • Cancer

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 104 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Japanese Participants Only: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
  • Chinese Participants Only: To qualify as Chinese for the purpose of this study, all 4 of the participants' biological grandparents must be of exclusive Chinese descent and born in China, Hong Kong, Macau, or Taiwan.
  • Have a (BMI) at the time of screening within the range 18.5 to 30 kilogram per meter squared (kg/m²) (inclusive).
  • Participants assigned female at birth (AFAB) not of and participants assigned male at birth (AMAB) willing to practice effective throughout the study may participate.
  • Willingness to undergo study procedures which may include repeated lumbar punctures

Exclusion criteria

Exclusion Criteria:

  • Are individuals of (IOCBP). Notwithstanding their IOCBP status, participants AFAB are excluded if they are breastfeeding.
  • A history of additional risk factors for Torsades de Pointes (for example, heart failure, hypokalemia, family history of Long Syndrome).
  • The use of concomitant medications that prolong the QT/QTc interval.
  • Have known allergies to LY4066708 or any components of the formulation, or history of allergic reactions to any transferrin receptor (TfR) antibodies.
  • Have participated, within the 3 months of screening, in a clinical trial involving a study intervention (other than the study intervention used in this study). If the previous product has a long half-life (t½), 3 months or 5 half-lives (whichever is longer) should have passed.
  • Are persons who have previously completed or withdrawn from this study and have previously received the study intervention. This exclusion criterion does not apply to subjects who are allowed to rescreen prior to randomization.
  • Have a 12-lead (ECG) abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study, or may confound ECG data analysis.
  • Show evidence of and/or positive hepatitis C antibody.
  • Current infection with virus (HBV) or evidence of past infection with HBV, that is, positive for Hepatitis B surface antigen (HBsAg) or Hepatitis B core total antibody (anti-HBc).
  • A marked baseline prolongation of time from the start of the Q wave to the end of the T wave/ corrected QT interval (QT/QTc) interval (for example, repeated demonstration of a corrected time from the start of the Q wave to the end of the T wave interval - Fridericia formula (QTcF) interval greater than 450 ms).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Part A Cohort 1: Single-Ascending Dose (SAD)- LY4066708

    LY4066708 administered by intravenous (IV) injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 2: SAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 3A: SAD- LY4066708

    LY4066708 administered by subcutaneous (SC) injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 3B: SAD- LY4066708

    LY4066708 administered by SC injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 4: SAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 5: SAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 5A: SAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 6A: SAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part A Cohort 6: SAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part B Cohort 1: Multiple-Ascending Dose (MAD)- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part B Cohort 2: MAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part B Cohort 3: MAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Experimental
    Part B Cohort 4: MAD- LY4066708

    LY4066708 administered by IV injection

    Drug: LY4066708

  • Placebo comparator
    Placebo

    Placebo administered by IV injection

    Drug: Placebo

  • Placebo comparator
    Placebo- Part A Cohort 3A and Part A Cohort 3B.

    Placebo administered by SC injection

    Drug: Placebo

Interventions

  • DrugLY4066708

    Administered IV

  • DrugPlacebo

    Administered IV

  • DrugLY4066708

    Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module

    Time frame: Baseline up to Week 12

  2. Part B: Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module

    Time frame: Screening to Day 22

Secondary outcomes

  1. Part A: Pharmacokinetics (PK)- Area Under the Plasma Concentration Versus Time Curve (AUC0-168)

    To evaluate PK after a single dose of LY4066708

    Time frame: Predose up to day 15

  2. Part B: Pharmacokinetics (PK)- AUC0-168

    To evaluate PK after multiple doses of LY4066708

    Time frame: Day 1 up to day 7

  3. Part A: Pharmacokinetics (PK)- Maximum Observed Drug Concentration (Cmax)

    To evaluate PK after a single dose of LY4066708

    Time frame: Predose up to day 15

  4. Part B: Pharmacokinetics (PK)- Cmax

    To evaluate PK after a single dose of LY4066708

    Time frame: After dose 3, up to day 64

07

Study locations

1 of 1 sites recruiting
  • Fortrea Clinical Research Unit
    Holbeck, Leeds, LS11 9EH, United Kingdom
    Recruiting
    • · Contact1-866-429-3700
    • Firas Almazedi · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 28 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jul 1, 2025
StartActual
May 13, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07046559
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
May 13, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion